Company Description
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States.
The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase 2a clinical trial for the treatment of atopic dermatitis and alopecia areata.
Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020.
It is also discovering and developing the ADX-096, a C3d – CR1 fusion protein, and other earlier stage assets, including C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.
The company was founded in 2017 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Jodie Morrison |
Contact Details
Address: 830 Winter Street Waltham, Massachusetts 02451 United States | |
| Phone | 781 999 0232 |
| Website | q32bio.com |
Stock Details
| Ticker Symbol | QTTB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001661998 |
| CUSIP Number | 746964105 |
| ISIN Number | US7469641051 |
| Employer ID | 47-3468154 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jodie Pope Morrison | Chief Executive Officer and Director |
| Dr. Shelia M. Violette Ph.D. | Co-founder, Chief Scientific Officer and President of Research |
| Dr. Jason A. Campagna M.D., Ph.D. | Chief Medical Officer |
| Lee H. Kalowski M.B.A. | Chief Financial Officer and President |
| Dr. Saul W. Fink Ph.D. | Chief Technology Officer |
| David Appugliese J.D. | Senior Vice President and Head of People |
| Maria Marzilli M.P.H. | Executive Vice President of Corporate Strategy and Program Operations |
| Kathryn E. Golden M.B.A. | Head of Chemistry, Manufacturing and Controls |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 11, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 11, 2025 | 424B3 | Prospectus |
| Mar 11, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 424B3 | Prospectus |
| Mar 10, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | 424B3 | Prospectus |
| Feb 10, 2025 | 8-K | Current Report |
| Feb 10, 2025 | SCHEDULE 13G | Filing |